Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Anakinra Treatment for Patients With Persistent Respiratory Symptoms Post Acute Covid and Immune System Activation: the Precision Double-blind, Randomized Clinical Trial

NCT05926505 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT05926505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05926505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Anakinra Treatment for Patients With Persistent Respiratory Symptoms Post Acute Covid and Immune System Activation: the Precision Double-blind, Randomized Clinical Trial
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 6, 2023
Completion date
March 31, 2028
Enrollment
182 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

long covid, post-acute covid-19, post-acute covid-19 syndrome